40 articles
Aponermin
Aponermin (埃普奈明, Shaite/沙艾特) is a recombinant circularly permuted TRAIL, the first approved DR4/DR5 agonist, approved in China in November 2023 with thalidomide and dexamethasone for relapsed/refractory multiple myeloma.
Atezolizumab regimen
An atezolizumab regimen is a cancer treatment schedule built around atezolizumab (Tecentriq), an anti-PD-L1 antibody given alone or with chemotherapy, approved in the US since 2016.
Atezolizumab/bevacizumab regimen
The atezolizumab/bevacizumab regimen is a cancer drug combination pairing a PD-L1 checkpoint inhibitor with an anti-VEGF antibody, approved in 2020 as standard first-line therapy for unresectable liver cancer after the IMbrave150 trial.
Avelumab plus axitinib
Avelumab plus axitinib is a combination cancer therapy pairing the PD-L1 antibody avelumab with the oral kinase inhibitor axitinib, approved in 2019 as first-line treatment for advanced renal cell carcinoma.
Axitinib and pembrolizumab regimen
The axitinib and pembrolizumab regimen pairs an oral targeted drug with an intravenous immunotherapy drug, approved in the US in 2019 as first-line treatment for advanced kidney cancer.
Bacillus Calmette–Guérin immunotherapy
Bacillus Calmette–Guérin (BCG) immunotherapy is the standard treatment for non-muscle-invasive bladder cancer: a weakened tuberculosis bacterium is instilled into the bladder weekly to provoke an immune attack on tumor cells.
Bendamustine and rituximab regimen
The bendamustine and rituximab (BR) regimen is a chemoimmunotherapy combination pairing the alkylating drug bendamustine with the antibody rituximab, given in up to six 28-day cycles for B-cell malignancies including indolent lymphoma and CLL.
Bevacizumab and temozolomide regimen
The bevacizumab and temozolomide regimen is a combination drug treatment pairing bevacizumab, an anti-VEGF antibody, with temozolomide, an oral alkylating chemotherapy, used mainly in glioblastoma.
Bevacizumab monotherapy
Bevacizumab monotherapy is the use of the monoclonal antibody bevacizumab alone, without chemotherapy, to block tumor blood vessel growth; its only approved single-agent use is recurrent glioblastoma in adults.
Bevacizumab/carboplatin regimen
The bevacizumab/carboplatin regimen is a combination chemotherapy regimen pairing the antibody bevacizumab with carboplatin, used mainly as first-line treatment of advanced non-squamous non-small cell lung cancer.
Bevacizumab/cetuximab regimen
The bevacizumab/cetuximab regimen is a combination of two monoclonal antibodies studied for metastatic colorectal cancer; trials showed worse survival and more toxicity, so it was never approved.
Bevacizumab/irinotecan regimen
The bevacizumab/irinotecan regimen combines bevacizumab, an antibody that starves tumors of blood supply, with irinotecan, a topoisomerase inhibitor, given intravenously every two weeks, mainly for recurrent glioblastoma.
Bevacizumab/paclitaxel regimen
The bevacizumab/paclitaxel regimen combines the anti-VEGF monoclonal antibody bevacizumab with the taxane chemotherapy paclitaxel, used to treat recurrent or metastatic cervical cancer and ovarian cancer, first approved in 2014.
Bintrafusp alfa
Bintrafusp alfa (M7824), a Merck KGaA/EMD Serono bifunctional anti-PD-L1/TGF-β trap fusion protein for cancer; its phase 3 NSCLC trial versus pembrolizumab failed and development was discontinued.
Cabozantinib/nivolumab regimen
The cabozantinib/nivolumab regimen combines the oral kinase inhibitor cabozantinib (Cabometyx) with the PD-1 inhibitor nivolumab (Opdivo), approved in 2021 for first-line advanced renal cell carcinoma.
Carboplatin and trastuzumab regimen
The carboplatin and trastuzumab regimen pairs the platinum chemotherapy carboplatin with the anti-HER2 antibody trastuzumab, usually with a taxane, and is used mainly in HER2-positive breast cancer.
Carboplatin, paclitaxel, and nivolumab regimen
The carboplatin, paclitaxel, and nivolumab regimen combines two chemotherapy drugs with the checkpoint inhibitor nivolumab, given intravenously, and is best established as neoadjuvant treatment of resectable non-small cell lung cancer.
Cenopodlin
Cenopodlin (CA-170, AUPM-170) is an oral small-molecule antagonist of PD-L1, PD-L2, and VISTA developed by Aurigene and licensed to Curis; the first oral immune checkpoint inhibitor in trials, now in phase 3 NSCLC testing, with disputed PD-L1 binding.
Chlorambucil and obinutuzumab regimen
The chlorambucil and obinutuzumab regimen is a chemoimmunotherapy combination pairing oral chlorambucil with the anti-CD20 antibody obinutuzumab, approved in 2013 for previously untreated chronic lymphocytic leukemia.
Cintredekin besudotox
Cintredekin besudotox (IL13-PE38QQR), an interleukin-13 Pseudomonas exotoxin A fusion protein for malignant glioma, given by convection-enhanced delivery; its PRECISE phase III trial failed to beat Gliadel wafers and it was never approved.
Cretostimogene grenadenorepvec
Cretostimogene grenadenorepvec (CG0070) is an intravesical oncolytic adenovirus immunotherapy by CG Oncology for BCG-unresponsive NMIBC; phase III BOND-003 showed 75% complete response with no grade 3 or higher adverse events.
DRF-7295
DRF-7295 (DRF 7295) was Dabur Research Foundation's peptide-based anticancer vaccine candidate, a mix of four neuropeptide analogues, in Indian Phase 1 (2002) and Phase 2 (2004) trials, abandoned after 2008.
Epacadostat
Epacadostat (INCB024360) is Incyte's oral IDO1 inhibitor for cancer immunotherapy. Its phase 3 melanoma trial ECHO-301/KEYNOTE-252 showed no benefit over pembrolizumab alone, halting most development.
Feladilimab
Feladilimab (GSK3359609) is GSK's humanized ICOS agonist IgG4 antibody for solid tumors; first-in-human in INDUCE-1, its INDUCE-3 head and neck trial failed and development was discontinued.
Immune checkpoint inhibitor therapy
Immune checkpoint inhibitor therapy is a cancer treatment using antibodies that block CTLA-4, PD-1, or PD-L1, releasing anti-tumor immune activity; ipilimumab was first approved in 2011.
Immunochemotherapy
Immunochemotherapy, also called neoadjuvant immunochemotherapy, combines immune checkpoint inhibitors with cytotoxic chemotherapy to shrink tumors before surgery; since 2022 it has become standard care in several tumor types.
Lenvatinib plus pembrolizumab
Lenvatinib plus pembrolizumab is a combination cancer therapy pairing the oral kinase inhibitor lenvatinib with the anti–PD-1 antibody pembrolizumab, FDA-approved for advanced renal cell carcinoma and endometrial carcinoma.
Lifileucel
Lifileucel, sold as Amtagvi and formerly LN-144, is a T cell immunotherapy made from a patient's own tumor tissue, approved for advanced melanoma in 2024.
Mitolactol
Mitolactol (dibromodulcitol, DBD, NSC-104800, brands Elobromol and Mitolac) is a synthetic hexitol-derived alkylating antineoplastic that inhibits DNA synthesis via epoxide groups; studied in breast, cervical cancer, and melanoma, with myelosuppression and leukemogenesis as key risks.
Nadofaragene firadenovec
Nadofaragene firadenovec (Adstiladrin, rAd-IFNα/Syn3) is a nonreplicating adenoviral gene therapy delivering interferon alfa-2b, FDA approved December 2022 for BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, dosed intravesically every 3 months.